关于 Acalabrutinib API
治疗类别 Oncology(肿瘤)

CAS 编号
870524-78-5
API 技术
Small molecule
剂型
口服固体/胶囊
Dr Reddy's 开发状态
开发中
Mechanism of Action
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays an important role in the survival and growth of B cells. By blocking BTK, acalabrutinib can help to slow down or even stop the growth of cancer cells.
Indication
The FDA approved Acalabrutinib for the treatment of adult patients with Mantle Cell Lymphoma (MCL) has received at least one prior therapy. Chronic lymphocytic leukemia (CLL). Small lymphocytic lymphoma (SLL).
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!